Ayasdi Named Best of Show and Best Practices Winner at Bio-IT World2014
Ayasdi Shares Editors' Choice Best Practices Award With Collaborator The Icahn School of Medicine at Mount Sinai for Its Use of Ayasdi Cure to Battle Diabetes
MENLO PARK, CA and BOSTON, MA, May 02, 2014 (Menafn - Market wired via COMTEX) --Bio-IT -- Ayasdi (www.ayasdi.com) today announced the company was named the grand prize winner of both of the Bio-IT World 2014 awards.Ayasdi is the only company to be recognized for both an innovative solution, Ayasdi Cure, and for that solution's key role in a breakthrough medical discovery. The new Ayasdi Cure application was selected Best of Show grand prize winner for Informatics Tools and Data. Separately, Ayasdi and The Icahn School of Medicine at Mount Sinai were named the Bio-IT World 2014 Editors' Choice Best Practices Award grand prize winner for their collaboration and discovery in Diabetes research.
Best of Show Award: Ayasdi Cure Catalyzes Next Generation Precision Medicine Ayasdi Cure is a new application designed to help pharmaceutical and biotech companies accelerate the drug discovery process by 50% in the era of precision medicine. Ayasdi Cure runs on Ayasdi's award-winning machine learning platform, which merges hundreds of algorithms with Topological Data Analysis (TDA) and obviates the need for queries or coding.
According to a recent report by PhRMa, on average it takes 10-15years to develop a drug and costs more than 1.2B, with many industry estimates putting that cost even higher. By contrast, the Ayasdi Cure application streamlines the discovery process -- including Research and Discovery, Compound Selection, Preclinical Testing, ClinicalTesting, and Regulatory Review -- by rapidly identifying compounds,drug targets, biomarkers, and adverse events from a variety of public and private biological and clinical data. Ayasdi Cure reduces the time and cost associated with this process by lowering analysis time and discovering novel insights.
Best Practices Award: Innovating the Understanding of Type 2 Diabetes
Mount Sinai utilized Ayasdi Cure to analyze over 11,000 patient medical records paired with genetic data. With Ayasdi Cure, Mount Sinai was able to gain new breakthrough insights that can dramatically impact how Type 2 Diabetes patients are diagnosed and treated. Based on the shape of the data, Mt. Sinai discovered that Type 2 Diabetes is not a singular disease. This breakthrough in Precision Medicine can lead to more effective treatment protocols and better patient outcomes for all Type 2 Diabetes patients.
Bio-IT World's Best of Show and Best Practices programs recognize innovative solutions to important problems facing the Life Sciences industry, and are judged by a team of leading industry experts and Bio-IT World editors.
Separately at the Bio-IT World conference, Ayasdi announced technology partnerships with Intel and CLC bio. To learn more click here. Ayasdi also announced a partnership with U-BIOPRED. To read more, click here.
About Bio-IT World (http://www.Bio-ITWorld.com) Part of the Cambridge Healthtech Institute Media Group(http://www.chimediagroup.com), Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine. Through a variety of sources including, Bio-ITWorld.com,Weekly Update Newsletter and the Bio-IT World News Bulletins, Bio-ITWorld is a leading source of news and opinion on technology and strategic innovation in the life sciences, including drug discovery and development.
About Ayasdi Ayasdi is transforming how the world uses data to solve complex problems by automatically discovering and operationalizing insights from complex datasets. Founded in 2008 after a decade ofDARPA and NSF funded research at Stanford, the Ayasdi Platform executes and merges the results of hundreds of machine learning algorithms using Topological Data Analysis (TDA), enabling users to explore their data within interactive and intuitive applications.Funded by Khosla Ventures, Institutional Venture Partners, GEVentures, Citi Ventures, and FLOODGATE, Ayasdi's customers include General Electric, Citigroup, Anadarko, Boehringer Ingelheim, the University of California San Francisco (UCSF), and Mount Sinai Hospital. To learn more, visit www.ayasdi.com or follow us @ayasdi.
Ayasdi helps the world's biggest and most sophisticated organizations discover breakthroughs that change how we all live and work. People who share this passion can view Ayasdi career opportunities here.
Intel is a registered trademark of Intel Corporation in the United States and other countries.
PR Contact
Michael Lindenberger
Reidy Communications
Email Contact
415-531-1449
